Two Sigma Advisers
BXRX

Two Sigma Advisers’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Two Sigma Advisers’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-133
Closed -$239K – 2792
2021
Q1 		$239K Buy
133
+95
+250% +$190K ﹤0.01% 2303
2020
Q4 		$53K Buy
+38
New +$77.7K ﹤0.01% 2313

Other funds holding BXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Two Sigma Advisers's BXRX Position: Q2 2021 in Review

Two Sigma Advisers sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q2 2021, closing a stake of 133 shares — an estimated $239K sold.

Two Sigma Advisers first reported a position in BXRX in Q4 2020 and held it in 2 quarters. The position peaked at $239K in Q1 2021. 31 funds tracked by Wall St. Rank hold BXRX as of Q2 2021.

  • Two Sigma Advisers reported no remaining Baudax Bio, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Two Sigma Advisers sold 133 Baudax Bio, Inc. Common Stock shares in Q2 2021, an estimated $239K.
  • Two Sigma Advisers first reported a position in Baudax Bio, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Two Sigma Advisers's Baudax Bio, Inc. Common Stock position peaked at $239K in Q1 2021.
  • 31 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q2 2021.

Based on Two Sigma Advisers's 13F filing for Q2 2021, filed 16 Aug 2021.